ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
본 보고서에서는 특발성 혈소판 감소성 자반증(면역성 혈소판감소성 자반증)의 임상시험에 대해 조사 분석하여 각국의 임상시험수와 평균등록수의 데이터와 주요기업의 리뷰와 관련된 임상시험 목록 등을 제공합니다.
목차
표 목록
도표 목록
보고서 가이던스
GlobalData의 임상시험 보고서 커버 범위
임상시험:지역별
임상시험과 평균등록수: 국가별
아시아태평양의 임상시험에 기여하고 있는 주요 5개국
유럽의 임상시험에 기여하고 있는 주요 5개국
북미의 임상시험에 기여하고 있는 상위국
중동 및 아프리카의 임상시험에 기여하고 있는 주요 5개국
중남미의 임상시험에 기여하고 있는 주요 5개국
G7 국가의 임상시험: 혈액질환의 임상시험에서 차지하는 특발성 혈소판 감소성 자반증(면역성 혈소판 감소성 자반증)의 비율
G7 국가의 임상시험: 위상별
G7 국가의 임상시험 : 시험 상태별
E7 국가의 임상시험: 혈액 질환의 임상시험에 차지하는 특발성 혈소판 감소성 자반증(면역성 혈소판 감소성 자반증)의 비율
E7 국가의 임상시험 : 페이즈별
E7 국가의 임상시험 : 시험 상태별
임상시험: 페이즈별
진행중의 시험 : 페이즈별
임상시험: 시험 상태별
임상시험 : 엔드포인트 스테이터스별
일정 기간동안 채용된 피험자
임상시험 : 스폰서 유형별
저명한 스폰서
특발성 혈소판 감소성 자반증(면역성 혈소판 감소성 자반증) 치료의 임상시험에 참가하고 있는 주요 기업
저명한 약물
특발성 혈소판 감소성 자반증(면역성 혈소판 감소성 자반증)에 관한 최신 임상시험 뉴스
2025년 1월 22일: National Institute of Health, 겸상 적혈구증 환자를 대상으로 Rigel의 Fostamatinib를 연구중
2025년 1월 9일: Cyrus Biotechnology, 중증근무력증을 포함한 만성 IgG 유발성자가면역질환의 임상 후보로서 CYR212를 선택한 것을 발표
임상시험 프로파일 스냅샷
부록
JHS
영문 목차
영문목차
GlobalData's clinical trial report, "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura - Global Clinical Trials Review, 2025" provides an overview of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura Clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents
List of Tables
List of Figures
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials
Jan 22, 2025: Rigel's Fostamatinib Being Studied by National Institute of Health in Patients With Sickle Cell Disease
Jan 09, 2025: Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic Igg-Driven Autoimmune Disease Including Myasthenia Gravis
